Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)’. The study aims to demonstrate the superiority of maridebart cafraglutide over a placebo in reducing body weight among adults with type 2 diabetes who are overweight or obese.
The intervention being tested is maridebart cafraglutide, a drug administered subcutaneously in varying doses (high, medium, and low) over 72 weeks. The purpose is to assess its effectiveness and safety in weight management for the target population.
This study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. Both participants and investigators are masked to ensure unbiased results, with the primary goal being treatment.
Key dates for the study include its start on March 17, 2025, and the last update on August 6, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
Amgen’s ongoing study could significantly impact its stock performance, as successful outcomes may enhance its market position in diabetes treatment. Investors should watch for updates, as positive results could boost investor confidence and influence market dynamics, especially in comparison to competitors in the diabetes treatment space.
The study is currently recruiting, with further details available on the ClinicalTrials portal.